The antifungal activities and biological consequences of BMVC-12C-P, a carbazole derivative against Candida species. (8th July 2019)

• Record Type: Journal Article
• Authors: Shen, Mandy; Li, Pei-Tzu; Wu, Yan-Jia; Lin, Ching-Hsuan; Chai, Eric; Chang, Ta-Chau; Chen, Chin-Tin
• Is Part Of: Medical mycology. Volume 58:Number 4(2020)
• Page Start: 521
• Page End: 529
• Publication Date: 2019-07-08
• Subjects: Candida species -- BMVC-12C-P -- mitochondria -- fungicidal activity; Medical mycology -- Periodicals; Veterinary mycology -- Periodicals; Mycology -- Periodicals; Mycoses -- Periodicals; Pathogenic fungi -- Periodicals; 616.969005
• DOI: 10.1093/mmy/myz071
• Languages: English
• ISSNs: 1369-3786

Abstract

Abstract: Fungal infections, particularly Candida species, have increased worldwide and caused high morbidity and mortality rates. The toxicity and development of resistance in present antifungal drugs justify the need of new drugs with different mechanism of action. BMVC-12C-P, a carbazole-type compound, has been found to dysfunction mitochondria. BMVC-12C-P displayed the strongest antifungal activities among all of the BMVC derivatives. The minimal inhibitory concentration (MIC) of BMVC-12C-P against Candida species ranged from 1 to 2 μg/ml. Fluconazole-resistant clinical isolates of Candida species were highly susceptible to BMVC-12C-P. The potent fungicidal activity of BMVC-12C-P relates to its impairing mitochondrial function. Furthermore, we found that the hyphae growth and biofilm formation were suppressed in C. albicans survived from BMVC-12C-P treatment. This study demonstrates the potential of BMVC-12C-P as an antifungal agent for treating Candida infections.